💊 Liraglutide (Victoza)
Liraglutide is a once-daily subcutaneous injection in the GLP-1 receptor agonist class. It is used with diet and exercise to improve blood sugar control in type 2 diabetes, and to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. It must be prescribed by a doctor.
In Arabic: ليراجلوتايد (فيكتوزا)🏷️ Brand names & manufacturers
Packages shown are US-market (DailyMed). Brands available in Palestine are in the price section below.✅ What it is used for
- As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.
- To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) in adults with type 2 diabetes and established cardiovascular disease.
- Coadministration with other liraglutide-containing products is not recommended.
🧪 Active ingredient
The active ingredient is liraglutide, an analog of human GLP-1 that activates GLP-1 receptors on pancreatic beta cells, increasing insulin release when blood glucose is elevated, decreasing glucagon secretion in a glucose-dependent manner, and delaying gastric emptying.
🌿 Benefits
- Improved blood sugar control in type 2 diabetes.
- Reduced risk of major cardiovascular events in adults with established cardiovascular disease.
- One injection daily at any time, regardless of meals.
📝 How to use
- Injected subcutaneously once daily at any time of day, independent of meals, in the abdomen, thigh or upper arm.
- The dose is set by your doctor or pharmacist and increased gradually; do not change your dose on your own.
- Inspect the solution before each injection; use only if clear, colorless and free of particles.
- Rotate injection sites within the same region to reduce the risk of cutaneous amyloidosis.
- If used with insulin, give as separate injections and never mix; they may be injected in the same body region but not adjacent to each other.
- Use a new needle for each injection and never share the pen between patients, even if the needle is changed.
💊 Dosage forms
- Injection: 18 mg/3 mL (6 mg/mL) clear, colorless solution in a prefilled, single-patient-use pen delivering 0.6 mg, 1.2 mg, or 1.8 mg doses.
⚠️ Common side effects
- Nausea
- Diarrhea
- Vomiting
- Decreased appetite
- Dyspepsia
- Constipation
- Headache
- Nasopharyngitis
- Upper respiratory tract infection
- Back pain
🚨 Serious — seek medical help
- Acute pancreatitis (discontinue if suspected).
- Hypoglycemia, which can be severe when combined with insulin or insulin secretagogues, and is more likely in children.
- Acute kidney injury due to volume depletion from vomiting/diarrhea.
- Severe gastrointestinal adverse reactions.
- Serious hypersensitivity reactions, including anaphylaxis and angioedema.
- Acute gallbladder disease (gallstones or cholecystitis).
- Thyroid C-cell tumors (boxed warning; seen in rodents, human relevance not determined).
- Pulmonary aspiration during general anesthesia or deep sedation.
⛔ Do not use if
- Personal or family history of medullary thyroid carcinoma (MTC).
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Serious hypersensitivity reaction to liraglutide or any excipient of the product.
❗ Warnings & precautions
- Boxed warning: risk of thyroid C-cell tumors; report any neck mass, difficulty swallowing, shortness of breath, or persistent hoarseness to your doctor.
- Stop the drug and seek medical advice promptly if pancreatitis or a serious allergic reaction is suspected.
- Not recommended in patients with severe gastroparesis.
- Monitor renal function in patients with vomiting or diarrhea that could cause volume depletion.
- If gallstones or cholecystitis are suspected, gallbladder studies are indicated.
- Tell your healthcare provider about any planned surgery or procedure involving anesthesia or deep sedation.
- Never share a pen between patients.
🔄 Drug interactions
- Delays gastric emptying and may affect the absorption of oral medications taken at the same time; use caution.
- Combination with insulin or an insulin secretagogue (e.g., sulfonylurea) increases the risk of hypoglycemia; their dose may need reduction when starting.
- Do not combine with other liraglutide-containing products.
🤰 Pregnancy
Use during pregnancy only if the potential benefit justifies the potential risk to the fetus; animal studies showed adverse developmental outcomes. Poorly controlled diabetes in pregnancy also carries risks for mother and baby. Consult your doctor.
🍼 Breastfeeding
There are no data on the presence of liraglutide in human milk, effects on the breastfed infant, or on milk production; it was present in rat milk. The benefits of breastfeeding should be weighed against the mother's need for the drug; consult your doctor.
🧒 Children
Safety and effectiveness for glycemic control in type 2 diabetes have been established in patients aged 10 years and older. The risk of hypoglycemia was higher in pediatric patients regardless of insulin and/or metformin use. Not established in children under 10 years.
👴 Older adults
No overall differences in safety or effectiveness were observed between patients 65 years and older and younger patients.
🌡️ Storage
Before first use: store in a refrigerator (36–46°F / 2–8°C); do not freeze or place next to the cooling element, and do not use if frozen. After first use: the pen may be kept for 30 days at room temperature (59–86°F / 15–30°C) or in the refrigerator. Keep the cap on when not in use and protect from excessive heat and sunlight. Remove and safely discard the needle after each injection and store the pen without a needle attached.
⏰ Missed dose
If a dose is missed, resume the once-daily schedule with the next scheduled dose; do not take an extra dose or increase the dose to make up. If more than 3 days have passed since the last dose, restart at 0.6 mg daily and re-titrate at your healthcare provider's discretion.
🆘 Overdose
Overdoses have caused severe nausea, severe vomiting, and severe hypoglycemia. In case of overdose, contact a poison control center or seek medical help immediately; supportive treatment is given according to symptoms.
💰 Price & brands in your area
Local prices are currently available for Palestine; more countries are coming. Ask your pharmacist for local price and alternatives.
📍 Find the nearest pharmacy
Your location is used only in your browser to show nearby pharmacies — we don't store it.
Open in Google Maps👨⚕️ For healthcare professionals
Mechanism of action
Acylated human GLP-1 receptor agonist with 97% sequence homology to GLP-1(7-37); activates the Gs/adenylyl cyclase-coupled receptor in pancreatic beta cells, raising cAMP and causing glucose-dependent insulin release, lowering glucagon secretion, and delaying gastric emptying. Stable against DPP-4 and NEP degradation; plasma half-life about 13 hours after subcutaneous administration.
Labeled dosing
Adults (per label): start 0.6 mg SC once daily for one week (for GI tolerability; not effective for glycemic control), then 1.2 mg daily, then 1.8 mg daily if more control is needed after at least one week. Pediatric ≥10 years: start 0.6 mg daily, increase in 0.6 mg increments after at least one week as needed, maximum 1.8 mg daily. Final dosing is determined by the physician.
- Consider reducing the dose of insulin secretagogues or insulin when initiating therapy.
- Reinitiate at 0.6 mg if more than 3 days have elapsed since the last dose.
- Never mix with insulin in the same injection.
- Routine serum calcitonin monitoring or thyroid ultrasound is of uncertain value for early MTC detection.
- Monitor renal function in patients with adverse reactions that could lead to volume depletion.
- Immunogenicity-related events, including urticaria, were more common with liraglutide (0.8%) than comparators (0.4%).
🎓 Key points for students
- Class: GLP-1 receptor agonist given subcutaneously once daily.
- Mechanism: glucose-dependent insulin secretion, decreased glucagon, delayed gastric emptying.
- Boxed warning: thyroid C-cell tumors; contraindicated in MTC and MEN 2.
- Most common adverse reactions: nausea, diarrhea, vomiting, decreased appetite, dyspepsia, constipation.
- Serious events: pancreatitis, gallbladder disease, acute kidney injury, hypersensitivity, hypoglycemia with insulin/sulfonylureas.
- Half-life about 13 hours, supporting once-daily dosing.
EME runs your whole clinic: appointments with WhatsApp reminders, patient files, finance & inventory, a patient portal and a members-price medical store — with your data isolated and protected.
Try EME free How we protect your data❓ FAQ
What is liraglutide and what is it used for?
It is a once-daily subcutaneous injection that improves blood sugar control in type 2 diabetes and reduces the risk of major cardiovascular events in adults with established cardiovascular disease.
What are the most common side effects?
Nausea, diarrhea, vomiting, decreased appetite, dyspepsia, and constipation. Starting at a low dose and increasing gradually under your doctor's supervision helps reduce stomach side effects.
Who should not use liraglutide?
People with a personal or family history of medullary thyroid carcinoma, MEN 2, or a serious hypersensitivity reaction to the drug or its ingredients.
What should I do if I miss a dose?
Resume your normal schedule at the next dose and do not double up. If more than 3 days have passed, restart at a lower dose as directed by your doctor.
Can it be used during pregnancy or breastfeeding?
In pregnancy, only if the benefit justifies the risk to the fetus. For breastfeeding there are insufficient data; talk to your doctor.
How should I store the pen?
Refrigerate before first use. After first use it can be kept 30 days at room temperature or in the fridge, with the cap on, protected from heat and sunlight, and never frozen.
⚕️ For education only — not a substitute for advice from your doctor or pharmacist. Do not start or stop any medicine without advice. Source: official FDA drug label via openFDA (2025-10), simplified. Updated: 2026-11-16.
Saxenda🏭 Novo Nordisk Pharmaceutical Industries, LP
Victoza🏭 Novo Nordisk
Liraglutide🏭 Lupin Pharmaceuticals, Inc.
Liraglutide🏭 Biocon Pharma Inc.
Liraglutide🏭 Meitheal Pharmaceuticals Inc.